FDA Approves New Psoriasis Drug
Jan 21, 2015 | PRODUCT NEWS
The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx/Novartis) for adults with moderate to severe plaque psoriasis.
The European Commission approved the same drug on Jan. 19. Its active ingredient is an antibody that binds to interleukin-17A and interferes with inflammation. The binding prevents that protein from triggering the inflammatory response that results in psoriasis patches.